TITLE

Discovery and Pre-clinical Development of Antithrombotics from Hematophagous Invertebrates

AUTHOR(S)
Ledizet, Michel; Harrison, Lisa M.; Koski, Raymond A.; Cappello, Michael
PUB. DATE
January 2005
SOURCE
Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jan2005, Vol. 3 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bloodfeeding (hematophagous) parasites have evolved effective means of inhibiting mammalian thrombosis, thereby facilitating the acquisition and digestion of a bloodmeal. To date, specific inhibitors of coagulation and platelet function have been identified from numerous invertebrate species, representing an impressive array of convergent functional strategies. These parasite antithrombotics, in addition to playing a critical role in the diseases caused or transmitted by bloodfeeding invertebrates, may also serve as potentially useful therapeutic agents for the treatment of a variety of conditions associated with activation of thrombosis. A number of naturally occurring anticoagulants and platelet inhibitors have been evaluated in vivo, with some currently in varying stages of preclinical and clinical development. Because of the unique specificity and potency of parasite antithrombotics, these invertebrate natural products hold great promise for improving the treatment of a variety of human illnesses, including heart disease, stroke, and cancer.
ACCESSION #
15594386

 

Related Articles

  • INTRAVENOUS ADMINISTRATION OF FIBRINOLYSIN: ITS SYSTEMIC TOXICITY AND EFFECT UPON COMPONENTS OF THE COAGULATION MECHANISM. Moser, Kenneth M. // Angiology;Aug1959 Part 2, Vol. 10 Issue 4, p253 

    1. In the doses used, the toxic potential of fibrinolysin is limited primarily to temperature elevation. In the absence of prophylactic medication, a febrile reaction occurred in 44.4 per cent of the patients, and could be correlated only with the presence of extensive thrombotic material. 2....

  • Potential New Targets for Antithrombotic Therapy. Gruber, A.; Hanson, S.R. // Current Pharmaceutical Design;Nov2003, Vol. 9 Issue 28, p2367 

    Thrombosis is the collective term for diseases caused by the localized accumulation of circulating blood elements within the vasculature that result in vessel occlusion. Conventional antithrombotic drugs can inhibit thrombus growth by targeting coagulation pathways (e.g., heparin, warfarin) or...

  • Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors. Gould, W.R.; Leadley, R.J. // Current Pharmaceutical Design;Nov2003, Vol. 9 Issue 28, p2337 

    Coronary heart disease (CHD) is the leading cause of mortality and morbidity in the United States. Currently, there are approximately 12 million Americans with CHD, which is most frequently caused by atherosclerosis. The thrombotic complications of atherosclerosis, such as acute coronary...

  • Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients. Rosove, Michael H.; Brewer, Petronella M. C. // Annals of Internal Medicine;8/15/92, Vol. 117 Issue 4, p303 

    Presents a study that determined the clinical course and influence of antithrombotic therapy in patients with lupus anticoagulant or anticardiolipin antibodies after the first thromboembolic event. Description of recurrent thrombosis; Antithrombotic treatments; Coincident risk factors for...

  • Clinical and Experimental Experience with Factor Xa Inhibitors. Viles-Gonzalez, Juan F.; Gaztanaga, Juan; Zafar, Urooj M.; Fuster, Valentin; Badimon, Juan J. // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 6, p379 

    Cardiovascular disease is the major cause of mortality in the industrial world today. We are constantly moving towards new and better ways of fighting this epidemic. Advances have been made in various fields such as patient education, imaging techniques, interventional cardiology, and novel...

  • Kinins and Cardiovascular Diseases. Jin Bo Su // Current Pharmaceutical Design;Sep2006, Vol. 12 Issue 26, p3423 

    Kinins are synthesized from their precursors by different enzymes and participate in the regulation of cardiovascular function through bradykinin (BK) B1 and B2 receptors. They modulate blood coagulation by exerting antithrombotic and profibrinolytic actions. By activating B2 receptors that...

  • Routine Stocking Therapy after Deep Venous Thrombosis: A Clinical Dilemma. Ginsberg, Jeffrey S. // Annals of Internal Medicine;8/17/2004, Vol. 141 Issue 4, p314 

    The article presents information on the stocking therapy after deep venous thrombosis. The post-thrombotic syndrome is one of the most common and frustating chronic conditions that physicians encounter. Patients with acute venous thrombosis have pain and swelling of the affected extremity caused...

  • Peripheral Arterial Disease and Antithrombotic Therapy: Sometimes Less is More.  // Clinical Oncology Alert;Oct2007 Clinical Briefs in Primary, p20 

    The article provides information on a study which investigated the effects of antithrombotic therapy on peripheral arterial disease (PAD). In the study, published in the "New England Journal of Medicine," PAD patients were randomly assigned to either antiplatelet therapy alone or an antiplatelet...

  • TREATMENT OF CHRONIC THROMBOEMBOLISM WITH ARVIN, ORAL FIBRINOLYTICS AND STANDARD ANTICOAGULANTS. Kounis, Nicholas G.; Evans, W. Howel // Vascular Surgery;Mar/Apr1977, Vol. 11 Issue 2, p68 

    In five patients suffering from recurrent deep venous thrombosis and pulmonary embolism, a therapeutic combination was applied including Arvin, Fearnley's regime and standard anticoagulants. In two patients complete remission of the disease seemed to he achieved during the following two years....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics